Objective: This study aims to investigate the antitumour mechanism of ergosta-4,6,8(14),22-tetraen-3-one (ETO), extracted from Pholiota adiposa, in H22 tumour-bearing mice through integrated metabolomics and gut microbiota systems analysis. Methods: After establishing the H22 tumor mouse model, we performed serum metabolomics through nontargeted UHPLC-HRMS and conducted gut microbiota profiling. Result: ETO exhibited significant antitumor effects, with tumor inhibition rates of 59.74% (low dose) and 76.10% (high dose).Untargeted metabolomics revealed that molecules downstream of the tricarboxylic acid cycle, arachidonic acid and linoleic acid were upregulated. Gut microbiota analysis revealed ETO-mediated enrichment of beneficial bacteria (Firmicutes and Lactobacillus) and suppression of the harmful bacterial species Bartonella. Integrative analysis demonstrated a negative correlation between indole-3-acetonitrile and Bartonella. Conclusion: ETO can inhibit the growth of tumor cells, and its effect on liver and kidney damage is less than that of CTX. Linoleate, and L-tryptophan emerged as potential therapeutic targets, while Firmicutes and Lactobacillus enrichment suggests gut microbiota-mediated antitumor activity, providing novel insights for hepatocellular carcinoma treatment.